Summary
Modified citrus pectin (MCP) is a specialized form of pectin, a complex carbohydrate naturally found in the cell walls of fruits and vegetables, especially in citrus fruits such as oranges, lemons, and grapefruit. Through a specific modification process, the molecular weight and degree of esterification in pectin are reduced, making MCP more easily absorbed by the body. This modification gives MCP unique therapeutic properties that have made it a focus area in research and clinical practice.
In its natural form, pectin is known for its prebiotic properties and its ability to regulate blood sugar and cholesterol levels. Modified citrus pectin stands out by being far more bioavailable, which gives it a range of health benefits related to detoxification, immune modulation, anti-cancer properties, as well as protection of the heart, brain, gut, kidneys, and liver. MCP’s ability to inhibit galectin-3, a protein that plays a role in inflammation, fibrosis, and tumor growth, is one of the most important mechanisms behind its therapeutic effects.
Benefits and effects
Heavy metal detoxification
MCP acts as a natural chelator that helps the body remove harmful heavy metals such as lead, mercury, arsenic, and cadmium. Studies show that MCP increases the excretion of lead in children with elevated levels without affecting essential minerals such as calcium, magnesium, and zinc. In addition, MCP has been shown to contribute to the elimination of uranium, which is particularly relevant for people exposed to environmental toxins from industry and agriculture.
The mechanism behind this detoxification is MCP’s ability to bind selectively to toxic metals in the intestines and prevent their reabsorption, facilitating safe excretion through stool and urine. This process makes MCP an effective and gentle alternative to synthetic chelators, which can often lead to the loss of essential nutrients.
Anti-cancer properties
MCP has been studied for its anti-cancer properties, especially in relation to prostate cancer, breast cancer, lung cancer, and gastrointestinal cancer. Research shows that MCP inhibits tumor growth, reduces metastasis, and increases sensitivity to chemotherapy.
In one study, MCP was shown to reduce PSA levels in patients with prostate cancer, indicating slower disease progression. Another preclinical study showed that MCP inhibited the growth of breast cancer cells in animal models. MCP has also been shown to block galectin-3, which is involved in tumor cell adhesion and metastasis.
Immune system support
MCP has immunomodulatory effects that contribute to a balanced immune response. Studies show that MCP may increase the activity of natural killer cells (NK cells) and strengthen the body’s defense against infections. In addition, MCP has been shown to reduce systemic inflammation, which may be beneficial for individuals with autoimmune conditions.
A preclinical study showed that MCP could reduce inflammatory markers associated with sepsis-induced kidney injury, as well as reduce oxidative stress and neuroinflammation in diabetes.
Cardiovascular diseases
MCP has been shown to have protective effects on the heart and blood vessels, mainly through its ability to inhibit galectin-3, a key factor in the development of cardiac fibrosis and atherosclerosis. A study published in European Heart Journal showed that MCP reduced inflammation and fibrotic changes in myocardial tissue, which improved heart function.
In addition, MCP has been shown to reduce LDL cholesterol and triglycerides, thereby lowering the risk of cardiovascular disease.
Technical specifications
MCP is produced by enzymatic or pH-modified breakdown of natural pectin from citrus fruits. This results in a low molecular weight (<15 kDa) and a high proportion of galacturonic acid (>85 %), ensuring maximum bioavailability and effectiveness.
Disclaimer and reservation
Use of MCP should take place in consultation with qualified healthcare professionals. Keep out of reach of children. Uno Vita AS does not claim that MCP can cure disease.
Freedom of expression and the right to information
Uno Vita reserves the right to share publicly available research on health and wellness technologies in accordance with:
-
UN Human Rights (1948), Article 19: The right to freedom of opinion and expression.
-
The International Covenant on Civil and Political Rights (1966), Article 19: The freedom to seek, receive and impart information.
-
Section 100 of the Norwegian Constitution: Protection of freedom of expression.
-
The First Amendment of the United States Constitution: Protection of freedom of expression against government interference.
References
-
Eliaz, I. (2006). Clinical Toxicology, 44(2), 101-109.
-
Petersen, G. M., et al. (2018). Toxicology Reports, 5, 17-25.
-
Yan, J., & Katz, A. (2010). Journal of Cancer Research and Therapeutics, 6(3), 201-205.
-
Guess, B. W., et al. (2003). Journal of Urology, 169(2), 405-410.
-
Inohara, H., et al. (2002). Cancer Research, 62(7), 1973-1979.
-
Gunning, A. P., et al. (2013). Biochimica et Biophysica Acta, 1830(11), 4063-4075.
-
Jackson, C. L., et al. (2007). Immunology Letters, 112(2), 120-125.
-
Henderson, N. C., et al. (2013). Hepatology, 58(3), 1082-1095.
-
Wang, Y., et al. (2018). Translational Medicine, 10(4), 451-465.
-
Martinez-Martinez, E., et al. (2015). Cardiovascular Research, 107(3), 307-317.
-
Yu, L., et al. (2014). European Heart Journal , 35(24), 1606-1614.
-
Viskovic, K., et al. (2020). Diabetes & Metabolism, 46(1), 13-19.
